Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727

Utilising High Throughput Screening to Design Certain Semi-Synthetic Molecules as Strong Neuropharmacological Agents

Sweta Rai[1], Prashant Kumar[2], Dheeraj Chitara[3], Prakash Chandra Gupta[*1]

[1]School of Pharmaceutical Sciences Chhatrapati Shahuji Maharaj University Kanpur Uttar Pradesh India

[2]Q-Line Biotech Limited, Lucknow, India

[3]Department of Biotechnology, School of Science, JECRC University, Jaipur, India

[*]**Corresponding Author**

Dr. Prakash Chandra Gupta, Assistant Professor, School of Pharmaceutical Sciences, Chhatrapati Shahuji Maharaj University, Kanpur, India

(Received: 05 January 2026 Revised: 15 February 2026 Accepted: 05 March 2026)

KEYWORDS

High-throughput Screening (HTS), Semi-synthetic neuropharmacology, Drug discovery, Computer-aided drug design (CADD), Neurodegenerative disorders, Structure–activity relationship (SAR)

ABSTRACT:

High-throughput Screening (HTS) has emerged as a key approach in accelerating the discovery of neuropharmacological agents derived from semi-synthetic sources. The combination of natural product chemistry with modern computational and automation-based tools enables the rapid identification of bioactive molecules with therapeutic relevance in neurological disorders. Through the integration of computer-aided drug design (CADD) and automated assay systems, HTS allows the efficient evaluation of large compound libraries, facilitating early identification of promising leads and optimisation through structure–activity relationship (SAR) analysis.

Semi-synthetic molecules, modified from natural scaffolds, exhibit improved pharmacokinetic properties, enhanced brain permeability, and reduced systemic toxicity, offering significant advantages in the management of complex neurodegenerative and neuropsychiatric conditions such as Alzheimer's and Parkinson's diseases. Despite challenges related to assay complexity and data interpretation, recent advances in analytics and system biology are refining the predictive accuracy and throughput efficiency of HTS platforms.

Overall, the integration of HTS with semi-synthetic drug design provides a robust and sustainable framework for modern neuropharmacological research. This synergistic approach enhances the precision and speed of discovery, paving the way for the rational development of next-generation neurotherapeutics with improved clinical efficacy and safety.

Introduction:

The term "neuropharmacology" is formed by combining "neuro", which relates to the brain's neurons, and "pharmacology", the study of drugs. Put simply, neuropharmacology examines how neurotransmitters and neuromodulators influence the brain, particularly the central nervous system. The field has come a long way since its early days, when only four drugs were available; nowadays, neurologists have access to a wide range of approved medicines for use in various clinical situations.

Neuropharmacological drugs can be categorised into distinct groups. The first includes sedatives, analgesics, and other agents that act on the body's pharmacodynamics. The second consists of drugs that impact the central nervous system itself, such as hypnotics and antidepressants. The third category covers drugs with chemotherapeutic effects. The way these medicines influence the brain can differ significantly. Neurons communicate through synapses—tiny junctions where pre- and post-synaptic neurons meet and exchange chemical messages. The presynaptic neuron releases neurotransmitters, which are then taken up by the post-synaptic neuron. The brain contains hundreds of neurotransmitters, and medications may work by modifying their activity [1]. Neuroscience, sometimes referred to as neurobiology, is the broad scientific study of the nervous system, with a particular focus on the brain and its functions. Some of the primary topics discussed in neuroscience include neuropsychiatric disorders, the interconnections between different brain regions, and the regulation of emotions [1]. The most common ageing-associated neurodegenerative disorders of the central nervous system (CNS) are Alzheimer's

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727

disease (AD), Parkinson's disease (PD), and related dementias. These disorders affect over 17 million people worldwide [2] and 21 million people worldwide [3]. The global trend of population ageing is expected to double the number of people with AD, PD, and related dementias during the next 20 years. [4]. Over the past few decades, there has been a lot of study and attention on these neuropsychiatric illnesses since they place a significant financial burden on society [1]. In the past, neuroscientists and clinical pharmacologists have collaborated to create human models to assess the potential of specific medications or drug receptors (biological targets) as therapeutic therapy—Trist and associates (2014). Over 300 million people worldwide suffer from major depressive disorder (MDD), which can affect people of all racial and socioeconomic backgrounds [5]; [6].

Novel drugs targeted at severe disorders of the central nervous system (CNS) have a comparatively high failure rate when compared to most other areas of therapeutic research. The several pharmaceutical companies that have halted or significantly reduced their CNS programs serve as evidence of this. [7]; [8]. This is particularly true for "disease-modifying drugs," which are pharmaceuticals designed to alter the course of a disease or condition. When it comes to neurodegenerative diseases (NDDs), it is particularly severe. The promising drugs are often palliative treatments that have little influence on the symptoms of the disease and no effect on how the illness progresses. It can be challenging to find safe and effective drugs to treat various ailments. Finding and developing a viable treatment requires a deep comprehension of the underlying causes of illness and a seamless transition from candidate identification to clinical trial design. The pharmaceutical industry is one of the few sectors where most initiatives end in complete failure, even after substantial time and financial expenditure, despite being heavily regulated (for all the right reasons). Although the aircraft industry and other economic sectors are subject to comparable restrictions, the outcome of such an evaluation is rarely a completely unusable aircraft or the permanent denial of a marketing license for a new aircraft. We possess sufficient knowledge of the physics of flight to ensure that planes can fly, and an iterative process involving regulators ensures safe flight operations. This is not a given in the search and development of new drugs. There is never a guarantee that a treatment will be approved for commercialisation, and it is also assumed that pharmaceutical agents cannot cure any disease.

Natural substances and structural analogues have historically made substantial contributions to pharmacotherapy, especially for infectious diseases [9]. Several other naturally occurring bioactive compounds have shown promise as "leads" or model molecules for drug synthesis or semi-synthesis, in addition to the physiologically active bioactive molecules derived from plants that have been found to have direct therapeutic use as drug substances [10]

Recent scientific and technological developments have also helped to overcome these issues and open up new options, as seen by the complexity of bioassays employed in medicinal plant drug research [11]. A renewed interest in natural chemicals as potential therapeutic leads, particularly for combating antibiotic resistance, has emerged from these developments, which also provide "mode of action" data at the molecular level in a timely and accurate manner [10]. [12].

To discover new chemical components in medicinal plants, scientists with backgrounds in ethnobotany, pharmacognosy, pharmaceutics, medicinal chemistry, taxonomy, organic chemistry, molecular biology, biochemistry, microbiology, pharmacology, and plant ecology can now collaborate [13]. [14]. Extraction, species collection, chemical separation, structural identification, and bioassays are the five steps of traditional plant natural product separation chemistry methods. [15]. To discover new chemical components in medicinal plants, scientists with backgrounds in ethnobotany, pharmacognosy, pharmaceutics, medicinal chemistry, taxonomy, organic chemistry, molecular biology, biochemistry, microbiology, pharmacology, and plant ecology can now collaborate [13]. [14]. The five steps of conventional plant natural product separation chemistry procedures include extraction, species collection, chemical separation, structural identification, and bioassays.

1. The primary goal of developing semi-synthetic derivatives for neurological diseases is to produce targeted, safe, and effective treatment medications. These substances are intended to solve some of the main drawbacks of conventional synthetic medications and natural goods, including:

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727

2. Improving the biological activity and selectivity for particular targets of neurological disorders.

3. Enhancing pharmacokinetic characteristics, such as blood-brain barrier (BBB) penetration, distribution, metabolism, and absorption.

4. Less toxicity and adverse effects than traditional medications or parent natural chemicals.

5. By permitting chemical modification and optimisation of readily accessible natural scaffolds, issues related to a limited natural supply can be addressed.

6. Making it possible to build multi-target drugs for multifactorial neurodegenerative disorders, such as ALS, Parkinson's, and Alzheimer's, in which a single molecule can act on several pathways at once.[16]

Scope of Semi-synthetic Derivatives in the Treatment of Neurological Disorders

The following are some examples of semi-synthetic compounds used in neurodegenerative disorders:

Drug Development and Discovery: In contemporary neuropharmacology, semi-synthetic derivatives are a key area of interest. They help fill the pipeline of possible new medications for conditions like multiple sclerosis, stroke, Parkinson's, Alzheimer's, and Huntington's.[17]

Multi-target Therapy: To address the intricate pathophysiology of neurodegenerative diseases, these derivatives can be designed to interact with multiple neuroprotective and neuromodulatory targets (cholinesterase, NMDA receptors, oxidative stress pathways, and anti-inflammatory sites) within a single molecule.[18]

Improving Efficacy of Existing Drugs: Known medications can be chemically modified to improve their brain delivery, neuroprotective potential, or neuroinflammation-reducing qualities (e.g., edaravone and its analogues for ALS and stroke; coumarin, triterpenoids, or flavonoid derivatives).[19]

Addressing Drug-Resistance and Side Effects: Semi-synthetic derivatives can decrease tolerance development, reduce off-target interactions, and attenuate adverse effects observed with completely synthetic or pure natural medicines by improving molecular structure[20]

Sustainable Drug Production: Semi-synthesis enables the optimisation of structures and the utilisation of renewable natural resources, thereby making drug production more scalable and sustainable.

Combinatorial chemistry and hybrid molecules: this method broadens the chemical variety and produces novel compounds with therapeutic potential, especially for modifying multiple neurotransmitter systems or disease pathways.[21]

Instances of Current Developments

Analogues and Edaravone: New analogues exhibit improved BBB penetration and are utilised for ALS and stroke recovery.

Triterpenoid and flavonoid derivatives, such as asiaticoside, which is being developed to treat Parkinson's and Alzheimer's disease, have been shown to exhibit better neuroprotective and cognitive effects, while also reducing oxidative stress and neuroinflammation. Singh, K., and others, 2024

Other heterocyclic compounds include coumarin, with a focus on several processes, such as antioxidant activity, neuroprotection, and aggregation inhibition.

By enabling customised, robust, and multi-target therapies that leverage both the structural diversity of nature and the precision of chemical synthesis, semi-synthetic derivatives play a crucial role in bridging the gap between natural pharmacology and contemporary medicinal chemistry, thereby significantly expanding treatment options for complex neurological disorders.

Principles of High Throughput Screening:

A standard virtual screening methodology will fully predict the performance of ligands in a virtual chemical library. However, these libraries have gotten so big in the last ten years that it is impossible to overlook the computing cost of Screening. ZINC, a well-known library of commercially accessible compounds for virtual Screening, for instance, expanded from 700k to 120 million structures between 2005 and 2015 and currently contains about 1 billion molecules.5,6 The enormous size of ZINC is not unique; there are other listed virtual libraries with well over a billion substances.[22], [23]

The concept of accessible molecules is inherent in non-enumerated libraries, which can include a substantially

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727

greater number of potential compounds—between 1010 and 1020. (Li and others, 2020b) Even though there is disagreement over whether "bigger is better" when it comes to virtual Screening,12 these sizable virtual libraries are currently being used for Screening in

Overview of HTS methodology and technological advances

Compounds from various chemical libraries undergo high-throughput Screening against a legitimate target for a disease once it has been identified. The time and expense involved in a drug development process can be significantly decreased if the number of compounds employed for Screening is limited to a few hundred. Many phases in drug development initiatives can be made less time-consuming and more cost-effective by utilising computational methodologies. For instance, the experimental high-throughput Screening of a chemical library comprising 400,000 compounds for protein tyrosine phosphatase-1B yielded an IC50 value of less than 100 micro-M, indicating a 0.021% success rate in identifying ligands that may inhibit the enzyme. However, starting from a chemical library of 235,000 compounds, the success rate increased to 34.8% when a computational technique was employed in the initial screening step. Modern chemical spaces, which can contain billions of molecules, are too big for experimental high-throughput Screening. Computational methods on HPC systems are frequently used to address this issue. In this evaluation, we highlight some virtual screening software implementations currently available on the market that are suitable for high-end computers. In the sections that follow, we provide a broad overview of virtual screening (VS) issues and discuss the potential for parallelisation to enable the efficient use of the computing power provided by HPCs—the initial phase of medication creation [24]. In drug research and development, virtual screening techniques such as molecular docking, pharmacophore models, and similarity searching are frequently employed. Molecular docking-based virtual Screening (DBVS) has become one of the most popular virtual screening techniques due to its outstanding performance in resolving an increasing number of target protein structures. However, DBVS is frequently criticised for its poor accuracy. Positioning ligands into a protein active site and scoring and rating docked ligands are the two fundamental steps in this technique. Each step is not flawless. The majority of docking and scoring activities are receptor-specific, and findings on various receptors may contradict one another, as indicated by several studies conducted over the past decade. The same target protein may act differently when docked by different programs. Experimental binding affinities and the scores provided by scoring functions frequently have a weak association. To find the optimal parameters for specific protein targets, new types of analysis are required to increase the success rate of docking and scoring techniques. [24]

Table Docking and Scoring

SNO	Docking Software	License Type	Interface	Key Features	Force Field(s) for Ligand Preparation	Typical Workflow Steps
1	AutoDock / AutoDock Vina	Free (Open-source)	Command line & GUI	Flexible ligand handling, suitable for medium to large virtual screening sets, quick execution, broad use in research	MMFF94 for minimization, Gasteiger charges for partial charge assignment	1. Clean and prepare protein and ligand structures. 2. Define docking grid around the binding site. 3. Run docking for the compound set. 4. Rank results by predicted

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727

						binding affinity. 5. Export top candidates.[25]
2.	DOCK	Free (Academic)	Command line	Supports large molecule libraries, early and mature docking suite, uses binding sphere mapping for site definition	GAFF (General AMBER Force Field) for ligands	1. Prepare target and ligand coordinate files. 2. Generate spheres to represent binding pockets. 3. Perform docking. 4. Evaluate score and binding mode.[26]
3.	GOLD	Commercial	GUI & Command line	Uses genetic algorithms, strong ability to explore ligand flexibility, multiple scoring functions	CHARMM or AMBER	1. Prepare molecules and define target site. 2. Run flexible docking. 3. Rank ligands and check poses.[27]
4	Glide	Commercial (Schrödinger)	GUI & Command line	Highly accurate docking with different modes (HTVS, SP, XP), efficient for large database screening	OPLS_2005 or OPLS3	1. Prepare ligand and protein sets. 2. Generate docking grids. 3. Perform screening. 4. Analyse and pick potential hits[28].
5	FlexX	Commercial	GUI & Command line	Fragment-based docking ideal for initial lead finding	Internal scoring parameters based on MMFF	1. Break ligands into fragments. 2. Fit fragments into

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727

						the pocket. 3. Score and rebuild. 4. Select top-scoring ligands.[28]
6	ICM	Commercial	GUI & Command line	Handles receptor flexibility, integrates SAR and scoring	Proprietary force field derived from MMFF94	1. Prepare 3D structures. 2. Run flexible docking. 3. Rank and visualise hits.[27]
7	FRED / HYBRID / POSIT (OpenEye)	Commercial	GUI & Command line	Very fast exhaustive sampling, ligand-guided docking, and pose prediction	MMFF94 or OPLS	1. Prepare ligand library and target site. 2. Choose appropriate docking method. 3. Analyse ranked poses.[27]
8	PyRx	Free	GUI	Simple interface integrating AutoDock/Vina, supports batch runs	Uses MMFF94 and Gasteiger charges through AutoDock backend	1. Import ligands and protein. 2. Define docking area. 3. Run screening. 4. Export rankings.[27]
9	PyRx	LibDock (Discovery Studio)	Commercial	GUI	HotSpot feature-mapping based docking, suitable for high-throughput VS	
10.	LibDock (Discovery Studio)	CDOCKER (Discovery Studio)	Commercial	GUI	CHARMm-based molecular dynamics simulated annealing for flexible ligand docking	
11.	CDOCKER (Discovery Studio)	Commercial	GUI	CHARMm-based molecular dynamics simulated annealing for	CHARMM	1. Prepare protein and ligand structures. 2. Define

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727

				flexible ligand docking		binding region. 3. Run flexible docking with simulated annealing. 4. Score, rank, and visualise.[27], [28]
12.	CDOCKER (Discovery Studio)	Commercial	GUI	CHARMm-based molecular dynamics simulated annealing for flexible ligand docking	CHARMM	1. Prepare protein and ligand structures. 2. Define binding region. 3. Run flexible docking with simulated annealing. 4. Score, rank, and visualise.[27], [28]

Summary of Common Force Fields in Ligand Preparation

1. The Merck Molecular Force Field, or MMFF94/MMFF94s, is a widely used tool for the virtual Screening of small, drug-like compounds.

2. • General AMBER Force Field, or GAFF, is compatible with AMBER biomolecular simulations, especially those using tiny organic ligands.

3. • CHARMM / CGenFF: CHARMM-based scoring or molecular dynamics are frequently utilised in protein-ligand docking.

4. The OpenEye package and Schrödinger's Glide both use Optimised Potentials for Liquid Simulations (OPLS, 2005/3).

5. • Gasteiger Charges: Vina, PyRx, and AutoDock all use fast partial charge assignment to prepare ligands quickly.[26], [27], [28]

Semi-synthetic Molecule design

Natural products were employed as excellent starting points for analogue design and synthesis. Although the valuable lead compounds are natural products, rarely can these products be directly employed in clinical applications Hence, structural modifications of natural products are essential in several cases because the inspection of modern research revealed that natural products and their semi-synthetic derivatives are valuable sources of new drug candidates with a variety of biological as well as pharmacological activities During the years1981e2014 natural products and their semi-synthetic derivatives have accounted for 25% of all newly approved drugs It is interesting to note that semi-synthetic derivatives represent the central part (21%) of the contribution. Increasing lipophilicity and inserting halogen atoms in natural products are excellent examples of modifications that enhanced the biological activity. The plan of action for semi-synthesis aims to enhance selectivity and therapeutic efficacy, improve physicochemical and pharmacokinetic properties, and

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727



create patentable compounds. Realising the physicochemical activities of natural products to simplify drug development is no different from [29]



Figure 1: Workflow for employing HTS in compound selection and optimisation using virtual Screening

When it comes to incorporating high-throughput Screening (HTS) into the design of semi-synthetic neuropharmacological agents, automated screening platforms and assay development are essential. Extensive libraries of compounds can be quickly and effectively evaluated using HTS to find those with promising biological action against neurological targets. Thousands of tests are carried out concurrently with excellent precision and reproducibility thanks to fully automated systems that integrate robotics, sensitive detectors, sophisticated liquid handling, and data analysis software.

Researchers can test semi-synthetic compounds for their impact on intricate brain pathways and neuronal targets in neuropharmacology using automated HTS platforms. Developing dependable, scalable biological tests that replicate pertinent neuronal environments—such as receptor-based assays or cell-based models of neurodegenerative diseases—is the primary goal of assay development. These tests are designed to identify minute

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727

alterations in protein aggregation, signalling, or neuronal activity with great sensitivity and selectivity.[30]

Because fewer reagents and compounds are required due to advancements in automation and miniaturisation, expenses are decreased, and throughput is increased. By optimising screening procedures, enhancing data interpretation, and ranking compounds with the most significant therapeutic promise, the integration of artificial intelligence further advances assay development. The development of novel semi-synthetic neuropharmacological agents with enhanced efficacy and safety profiles is accelerated by this collaboration between automation, HTS, and AI.[31]

Overall, automated screening platforms coupled with well-designed assays form the backbone of modern HTS strategies in neuropharmacology, shortening drug discovery timelines and increasing the chances of finding effective treatments for neurological disorders while maintaining high standards of scientific rigour and reproducibility. This approach transforms traditional drug discovery into a faster, more innovative, and more targeted process.[32]

How do automation platforms enhance neuropharmacological research?

Throughout the drug discovery and development process, automation systems significantly enhance productivity, accuracy, and repeatability, thereby benefiting neuropharmacological research. Researchers can perform extensive screenings of neuroactive substances more quickly and with fewer human errors thanks to these platforms, which combine robotics and sophisticated instrumentation to manage massive volumes of samples and intricate experiments. Automation guarantees consistent test execution, yielding dependable and reproducible results that increase the trustworthiness of experimental findings.[33]

Automation enables the high-throughput testing of substances on neuronal cells, receptors, and biochemical pathways, making it easier to explore complex brain-related targets in neuropharmacology. Automated platforms, combined with advanced data analysis technologies such as machine learning and artificial intelligence (AI), prioritise promising drug candidates, optimise experimental conditions, and interpret vast datasets. This combination minimises resource consumption and shortens the time required to identify compounds with potential therapeutic effects.[34]

Additionally, automation facilitates the creation of sophisticated tests, such as 3D cell cultures and disease-relevant models, that more closely resemble the brain environment. More physiologically relevant data are made possible as a result, which is essential for creating effective neuropharmacological drugs. Additionally, automation increases scalability, enabling the efficient testing of thousands to millions of samples, and improves safety by minimising direct human contact with hazardous substances.[24]

All things considered, automated platforms are revolutionising neuropharmacological research into a faster, more accurate, and highly scalable field, poised to spur new therapeutic discoveries for neurological disorders by simplifying processes, reducing errors, and facilitating complex data-driven decisions.[34]

Hit identification and lead optimisation are crucial steps in the drug discovery process, particularly in designing neuroactive agents through high-throughput Screening (HTS).

Hit Identification and HTS Data Analysis

Finding "hits"—molecules exhibiting desired biological activity—in HTS entails screening hundreds of thousands of compounds against a biological target. These hits serve as the foundation for additional therapeutic development. Following Screening, data analysis helps identify these hits by assessing the activity and repeatability of each compound using statistical techniques such as z-scores or % inhibition. To verify their impact and eliminate false positives, hits are subjected to secondary tests. To narrow down the list to suitable candidates for further research and development, this step is crucial.[30]

Hit-to-Lead Progression

After hits are identified, they undergo recurrent testing and optimisation cycles to become lead compounds. Along with potency, hit-to-lead progression involves assessing variables like pharmacokinetics, toxicity, and bioavailability. Through the gradual evolution of hits toward clinical prospects, medicinal chemists refine these leads by modifying chemical structures to enhance

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727

activity and improve drug-like properties. This procedure strikes a balance between maintaining an appropriate metabolism and a safe profile, while also enhancing target engagement.[30]

Structure-Activity Relationship (SAR) Insights

SAR studies analyse how different chemical modifications affect a compound's biological activity. Through systematic variation of chemical groups and testing their effects on the target, researchers derive relationships that guide the optimisation process. SAR data are foundational for understanding which molecular features are crucial for activity and can inform the design of improved semi-synthetic neuropharmacological agents with higher potency and selectivity.[32]

Medicinal Chemistry Strategies for Optimisation

1. Medicinal chemistry plays a crucial part in the refinement of neuroactive drugs by:

• Blocking or altering polar groups that lessen receptor binding or brain penetration,

1. • Improving favourable pharmacokinetics and metabolic stability.

2. • Reducing toxicity and off-target effects.

3. • Including structural elements that improve penetration of the blood-brain barrier.

4. By improving the efficacy, safety, and drug-likeness of lead compounds, this calculated chemical alteration brings them closer to being promising treatment candidates for neurological conditions.[30]

Challenges and Limitations

Present challenges in the use of HTS for neuropharmacological hits include limitations in assay equipment, data complexity, and the occurrence of false positives and negatives.

• Particular difficulties in designing semi-synthetic molecules [35]

1. • Difficulties and Restrictions Present challenges in the use of HTS for neuropharmacological hits. Assay system limitations, data complexity, and false positives/negatives. Particular difficulties in designing semi-synthetic compounds. • When it comes to neuropharmacological hit discovery, especially for semi-synthetic molecules, high-throughput Screening (HTS) has several difficulties and restrictions.[36]

Current Obstacles in HTS Application for Neuropharmacology

Present challenges in the use of HTS for neuropharmacological hits include limitations in assay equipment, data complexity, and the occurrence of false positives and negatives.

• Particular difficulties in designing semi-synthetic molecules [35]

• Difficulties and Restrictions Present challenges in the use of HTS for neuropharmacological hits. Assay system limitations, data complexity, and false positives/negatives. Particular difficulties in designing semi-synthetic compounds. • When it comes to neuropharmacological hit discovery, especially for semi-synthetic molecules, high-throughput Screening (HTS) has several difficulties and restrictions.[34]

Limitations of Assay Systems and Data Complexity

Large amounts of complicated, multiparametric data can be produced by HTS assays, particularly when cell-based or high-content Screening is employed. The management, processing, and interpretation of this data remain challenging tasks. False positives and negatives are serious problems because assay sensitivity or variability can cause small but real activities to go unnoticed, while non-specific substances may appear active. Although statistical techniques, quality control, and data standardisation are essential, these errors can never be eliminated. Furthermore, data complexity is increased by batch effects, plate inconsistencies, and experimental noise, all of which necessitate robust computational frameworks and specialised expertise to manage.

Specific Challenges in Semi-Synthetic Molecule Design

Semi-synthetic neuropharmacological drugs frequently add chemical complexity by combining synthetic alterations with natural scaffolding. Unpredictable biological interactions resulting from innovative alterations, uncontrolled or variable synthetic pathways, and challenges in maintaining constant purity and stereochemistry are all part of the optimisation process for these compounds. Their intricate architectures may

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 174-187 | ISSN:2251-6727

also impact metabolic stability, permeability, solubility, and assay compatibility, making Screening and lead optimisation more challenging. Furthermore, semi-synthetic chemicals may have unidentified off-target effects, making it more challenging to interpret the results of screening data.[36]

Future Perspectives and Emerging Trends

The future of high-throughput Screening (HTS) using computer-aided drug design (CADD) technologies is being transformed by AI-driven platforms, high-content Screening, and integration with computational approaches and systems biology, especially for semi-synthetic neuropharmacological research.[24]

Advances in HTS Using CADD Technologies

Through better candidate selection and assay optimisation, artificial intelligence (AI) and machine learning are increasing the specificity and efficiency of HTS. Among the significant developments are: • AI-driven predictive models improve screening criteria and lower false positives and negatives.

• By analysing intricate biological and chemical data, deep learning enhances assay design and hit detection while forecasting compound behaviours.

• Data-driven simulations and generative design quickly investigate different compound chemistries and optimise molecular structures.

1. High-content screening tools enhance our understanding of neuropharmacological mechanisms by interpreting cellular responses and phenotypic alterations using AI-based image analysis.[33]

Integration with Computational Drug Design & Systems Biology

There is a growing trend towards integrating HTS data with computational drug design, allowing:

1. The use of molecular docking, molecular dynamics simulations, and binding free energy predictions to optimise lead compounds identified in HTS campaigns.

2. Systems biology tools merging omics data with HTS results to map network effects and identify multi-target agents for complex neural pathways.

3. Computational pipelines leveraging big data from genomics, proteomics, and chemical libraries to enable high-throughput virtual Screening beyond traditional laboratory constraints.[33]

Predicted Trends in Semi-Synthetic Neuropharmacological Research

1. These new developments will influence studies in semi-synthetic neuropharmacology:

2. By predicting multi-target neuropharmacological profiles and accelerating the development of new scaffolds, AI integration will enable the quicker optimisation of semi-synthetic analogues.

3. AI-powered personalised and targeted screening methods will adjust compound selection according to patient-specific information, potentially transforming the way neurological illnesses are treated.

4. Through dispersed, real-time workflows, cloud-based research platforms, and collaborative data sharing, international neuropharmacology initiatives can be facilitated, dismantling barriers between academia and industry.

• Data-driven compound repurposing: By mining and connecting Screening and clinical databases, machine learning models will find novel applications for already-approved neuropharmacological drugs and shorten development times.

• To ensure practical utility and regulatory acceptability in drug discovery pipelines, there will be an increasing emphasis on interpretable and robust AI models. [24]

All things considered, these patterns point to a future in which semi-synthetic neuropharmacological research is radically transformed by interdisciplinary, data-rich, and intelligent platforms, which will accelerate the process of synthesising compounds and bringing them into clinical use.

Conclusion: High-throughput Screening (HTS) has emerged as a pivotal strategy in the discovery and rational design of semi-synthetic neuropharmacological agents, effectively bridging natural product chemistry with modern computational drug discovery. The integration of automated screening technologies, artificial intelligence (AI), and computer-aided drug design (CADD) facilitates the rapid assessment and

optimisation of extensive compound libraries against complex neurological targets. This convergence enhances hit identification, elucidation of structure–activity relationships (SAR), and lead optimisation, thereby expediting the development of potent, selective, and safe neuroactive compounds.

Semi-synthetic derivatives, derived from natural scaffolds, offer significant therapeutic promise in addressing multifactorial neurodegenerative and neuropsychiatric disorders such as Alzheimer's disease, Parkinson's disease, and major depressive disorder. Structural modifications within these molecules enable improved pharmacokinetic behaviour, enhanced blood–brain barrier permeability, and reduced off-target toxicity, providing distinct advantages over purely synthetic or natural analogues. The adoption of HTS platforms streamlines this process through high-throughput compound evaluation, data-driven analysis, and targeted molecular refinement.

Despite its transformative potential, challenges such as assay complexity, data interpretation, and the structural diversity of semi-synthetic compounds persist. However, recent advancements in AI-assisted analytics, high-content Screening, and systems biology approaches are progressively mitigating these limitations. Collectively, these innovations are fostering predictive, efficient, and sustainable neuropharmacological research pipelines.

In summary, the synergistic application of high-throughput Screening and semi-synthetic chemistry represents a paradigm shift in neurodrug discovery. This integrative framework, anchored in automation, computational intelligence, and molecular innovation, holds substantial potential to accelerate the translation of molecular insights into clinically relevant neurotherapeutics for the effective management of neurological disorders.

References

[1] A. W. K. Yeung, M. Heinrich, and A. G. Atanasov, "Ethnopharmacology—A Bibliometric Analysis of a Field of Research Meandering Between Medicine and Food Science?," *Front Pharmacol*, vol. 9, Mar. 2018, doi: 10.3389/fphar.2018.00215.

[2] C. Reitz and R. Mayeux, "Alzheimer's disease: Epidemiology, diagnostic criteria, risk factors and biomarkers," *Biochem Pharmacol*, vol. 88, no. 4, pp. 640–651, Apr. 2014, doi: 10.1016/j.bcp.2013.12.024.

[3] W. Poewe *et al.*, "Parkinson disease," *Nat Rev Dis Primers*, vol. 3, no. 1, p. 17013, Mar. 2017, doi: 10.1038/nrdp.2017.13.

[4] N. T. Tzvetkov and A. G. Atanasov, "Natural Product-Based Multitargeted Ligands for Alzheimer's Disease Treatment?," *Future Med Chem*, vol. 10, no. 15, pp. 1745–1748, Aug. 2018, doi: 10.4155/fmc-2018-0146.

[5] C. J. L. Murray and A. D. Lopez, "Evidence-Based Health Policy—Lessons from the Global Burden of Disease Study," *Science (1979)*, vol. 274, no. 5288, pp. 740–743, Nov. 1996, doi: 10.1126/science.274.5288.740.

[6] K. Smith, "Mental health: A world of depression," *nature*, vol. 515, no. 7526, pp. 180–181, Nov. 2014, doi: 10.1038/515180a.

[7] A. Abbott, "Novartis to shut brain research facility," *nature*, vol. 480, no. 7376, pp. 161–162, Dec. 2011, doi: 10.1038/480161a.

[8] G. Miller, "Is Pharma Running Out of Brainy Ideas?" *Science (1979)*, vol. 329, no. 5991, pp. 502–504, Jul. 2010, doi: 10.1126/science.329.5991.502.

[9] A. G. Atanasov *et al.*, "Natural products in drug discovery: advances and opportunities," *Nat Rev Drug Discov*, vol. 20, no. 3, pp. 200–216, Mar. 2021, doi: 10.1038/s41573-020-00114-z.

[10] M. Bahar, Y. Deng, J. N. Fletcher, and A. D. Kinghorn, "PLANT-DERIVED NATURAL PRODUCTS IN DRUG DISCOVERY AND DEVELOPMENT: AN OVERVIEW," in *Selected Topics in the Chemistry of Natural Products*, WORLD SCIENTIFIC, 2007, pp. 11–48. doi: 10.1142/9789812790781_0002.

[11] D. J. Newman, G. M. Cragg, and K. M. Snader, "The influence of natural products upon drug discovery (Antiquity to late 1999)," *Nat Prod Rep*, vol. 17, no. 3, pp. 215–234, 2000, doi: 10.1039/a902202c.

[12] Y. Duah Boakye, N. Osafo, C. Amaning Danquah, F. Adu, and C. Agyare, "Antimicrobial Agents: Antibacterial Agents, Anti-biofilm Agents, Antibacterial Natural Compounds, and

Antibacterial Chemicals," in *Antimicrobials, Antibiotic Resistance, Antibiofilm Strategies and Activity Methods*, IntechOpen, 2019. doi: 10.5772/intechopen.82560.

[13] W. Jones, Y.-W. Chin, and A. Kinghorn, "The Role of Pharmacognosy in Modern Medicine and Pharmacy," *Curr Drug Targets*, vol. 7, no. 3, pp. 247–264, Mar. 2006, doi: 10.2174/138945006776054915.

[14] F. E. Koehn and G. T. Carter, "The evolving role of natural products in drug discovery," *Nat Rev Drug Discov*, vol. 4, no. 3, pp. 206–220, Mar. 2005, doi: 10.1038/nrd1657.

[15] A. Kinghorn *et al.*, "Novel Strategies for the Discovery of Plant-Derived Anticancer Agents," *Pharm Biol*, vol. 41, no. sup1, pp. 53–67, Jan. 2003, doi: 10.1080/1388020039051744.

[16] F. Musso and B. Biscussi, "Commentary on the Obtention of Semi-synthetic Derivatives from Natural Products for Medicinal Applications: Advances, Challenges, and Perspectives," *Curr Med Chem*, vol. 32, no. 21, pp. 4147–4153, Jun. 2025, doi: 10.2174/0109298673336208241014102943.

[17] J. Tauchen, L. Huml, M. Jurášek, J. M. Regenstein, and F. Ozogul, "Synthetic and semi-synthetic antioxidants in medicine and food industry: a review," *Front Pharmacol*, vol. 16, Jul. 2025, doi: 10.3389/fphar.2025.1599816.

[18] K. Xu, X. Ren, J. Wang, Q. Zhang, X. Fu, and P.-C. Zhang, "Clinical development and informatics analysis of natural and semi-synthetic flavonoid drugs: A critical review," *J Adv Res*, vol. 63, pp. 269–284, Sep. 2024, doi: 10.1016/j.jare.2023.11.007.

[19] K. Singh *et al.*, "Recent Advances in the Synthesis of Antioxidant Derivatives: Pharmacological Insights for Neurological Disorders," *Curr Top Med Chem*, vol. 24, no. 22, pp. 1940–1959, Sep. 2024, doi: 10.2174/0115680266305736240725052825.

[20] B. Goel and S. K. Jain, "Semi-synthesis: Bridging natural products and novel anticancer therapies," *European Journal of Medicinal Chemistry Reports*, vol. 12, p. 100218, Dec. 2024, doi: 10.1016/j.ejmcr.2024.100218.

[21] F. Musso and B. Biscussi, "Commentary on the Obtention of Semi-synthetic Derivatives from Natural Products for Medicinal Applications: Advances, Challenges, and Perspectives," *Curr Med Chem*, vol. 32, no. 21, pp. 4147–4153, Jun. 2025, doi: 10.2174/0109298673336208241014102943.

[22] G. K. Kiriiri, P. M. Njogu, and A. N. Mwangi, "Exploring different approaches to improve the success of drug discovery and development projects: a review," *Futur J Pharm Sci*, vol. 6, no. 1, p. 27, Dec. 2020, doi: 10.1186/s43094-020-00047-9.

[23] H. Li, K. Sze, G. Lu, and P. J. Ballester, "Machine-learning scoring functions for structure-based drug lead optimisation," *WIREs Computational Molecular Science*, vol. 10, no. 5, Sep. 2020, doi: 10.1002/wcms.1465.

[24] K. Wang, Y. Huang, Y. Wang, Q. You, and L. Wang, "Recent advances from computer-aided drug design to artificial intelligence drug design," *RSC Med Chem*, vol. 15, no. 12, pp. 3978–4000, 2024, doi: 10.1039/D4MD00522H.

[25] N. A. Murugan, A. Podobas, D. Gadioli, E. Vitali, G. Palermo, and S. Markidis, "A Review on Parallel Virtual Screening Softwares for High-Performance Computers," *Pharmaceuticals*, vol. 15, no. 1, p. 63, Jan. 2022, doi: 10.3390/ph15010063.

[26] K. Onodera, K. Satou, and H. Hirota, "Evaluations of Molecular Docking Programs for Virtual Screening," *J Chem Inf Model*, vol. 47, no. 4, pp. 1609–1618, Jul. 2007, doi: 10.1021/ci7000378.

[27] A. Lacour, H. Ibrahim, A. Volkamer, and A. K. H. Hirsch, "DockM8: An All-in-One Open-Source Platform for Consensus Virtual Screening in Drug Design," Jul. 23, 2024. doi: 10.26434/chemrxiv-2024-17k46.

[28] E. Kellenberger, J. Rodrigo, P. Muller, and D. Rognan, "Comparative evaluation of eight docking tools for docking and virtual screening accuracy," *Proteins: Structure, Function, and Bioinformatics*,

vol. 57, no. 2, pp. 225–242, Nov. 2004, doi: 10.1002/prot.20149.

[29] S. Majhi and D. Das, "Chemical derivatisation of natural products: Semi-synthesis and pharmacological aspects- A decade update," *Tetrahedron*, vol. 78, p. 131801, Jan. 2021, doi: 10.1016/j.tet.2020.131801.

[30] H. Aldewachi, R. N. Al-Zidan, M. T. Conner, and M. M. Salman, "High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases," *Bioengineering*, vol. 8, no. 2, p. 30, Feb. 2021, doi: 10.3390/bioengineering8020030.

[31] S. Singh, R. Kumar, S. Payra, and S. K. Singh, "Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery," *Cureus*, Aug. 2023, doi: 10.7759/cureus.44359.

[32] T. Zhu *et al.*, "Hit Identification and Optimization in Virtual Screening: Practical Recommendations Based on a Critical Literature Analysis," *J Med Chem*, vol. 56, no. 17, pp. 6560–6572, Sep. 2013, doi: 10.1021/jm301916b.

[33] Z. Wu *et al.*, "Current perspectives and trend of computer-aided drug design: a review and bibliometric analysis," *International Journal of Surgery*, vol. 110, no. 6, pp. 3848–3878, Jun. 2024, doi: 10.1097/JS9.0000000000001289.

[34] D. Nickischer, L. Elkin, N. Cloutier, J. O'Connell, M. Banks, and A. Weston, "Challenges and Opportunities in Enabling High-Throughput, Miniaturized High Content Screening," 2018, pp. 165–191. doi: 10.1007/978-1-4939-7357-6_11.

[35] S. Nath *et al.*, "Lead optimisation against drug-resistant *Leishmania donovani* infection: Semi-synthetic derivatives of ethyl linoleate isolated from Indian edible mushroom *Meripilus giganteus*," Jul. 07, 2025. doi: 10.1101/2025.07.03.663049.

[36] R. Roy, S. K. Singh, N. Ahmad, and S. Misra, "Challenges and advancements in high-throughput screening strategies for cancer therapeutics," *Global Translational Medicine*, vol. 3, no. 1, p. 2448, Mar. 2024, doi: 10.36922/gtm.2448.